Skip to main content
Apt Medical Inc. logo

Apt Medical Inc. — Investor Relations & Filings

Ticker · 688617 ISIN · CNE100004C45 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2025-05-13 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688617

About Apt Medical Inc.

https://www.aptmed.com/

Apt Medical Inc. is a specialized developer and manufacturer of advanced medical devices for minimally invasive vascular interventions. The company focuses on the fields of electrophysiology, interventional cardiology, and peripheral vascular procedures. Its product portfolio includes diagnostic and ablation catheters, steerable sheaths, guide wires, microcatheters, and balloon catheters designed for complex cardiovascular treatments. Apt Medical emphasizes research and development to provide high-precision tools for clinicians, aiming to improve procedural outcomes in the treatment of cardiac arrhythmias and vascular diseases. The company serves a global market, providing integrated solutions for interventional procedures through a commitment to technological innovation and quality manufacturing standards.

Recent filings

Filing Released Lang Actions
2025年第一次独立董事专门会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from an independent directors' special meeting held by Shenzhen Huitai Medical Device Co., Ltd. It discusses approval of matters related to the cancellation and vesting of restricted stock incentive plans. The content focuses on board-level decisions and approvals rather than financial results, audit opinions, or shareholder voting outcomes. The document length is short (1116 characters) and it is a formal meeting resolution, not a full report or announcement of a report. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2025-05-13 Chinese
关于公司2021年限制性股票激励计划首次授予及预留部分授予B类限制性股票第三个归属期符合归属条件的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's 2021 restricted stock incentive plan, including specifics about stock grants, vesting periods, performance conditions, and board approvals. It discusses the granting and vesting of restricted stock to employees and the fulfillment of conditions for stock vesting. The content focuses on stock incentive plan implementation and related corporate governance matters. This type of document is typically classified as a Regulatory Filing (RNS) because it is an official announcement about stock incentive plan details and vesting results, not a financial report, earnings release, or management report. It is not a proxy solicitation, remuneration report, or capital change announcement, but a regulatory disclosure about stock incentives and their vesting status.
2025-05-13 Chinese
北京市嘉源律师事务所关于深圳惠泰医疗器械股份有限公司2021年限制性股票激励计划首次授予及预留部分授予B类限制性股票第三个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书
Regulatory Filings Classification · 10% confidence The document is a legal opinion letter issued by Beijing IIA Yuan Law Offices regarding Shenzhen Huitai Medical Devices Co., Ltd’s 2021 restricted stock incentive plan. It contains legal compliance checks, approvals, board resolutions, and vesting conditions rather than substantive financial statements or announcements of financial results. It is a certification/legal counsel opinion attached to a regulatory disclosure rather than the incentive plan itself or an earnings/annual report. Under the “Certification Rule,” such legal opinion letters are classified as Regulatory Filings (RNS).
2025-05-13 Chinese
关于选举职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an employee representative director to the company's board. It includes details about the election process, the individual elected, and compliance with relevant laws and regulations. There is no financial data, no mention of financial results, no report publication, or regulatory certification. The content focuses on changes in the board composition, specifically the election of a board member. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2025-05-13 Chinese
2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the Annual General Meeting (AGM) of Shenzhen Huitai Medical Devices Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2024 annual report, financial statements, profit distribution, board and supervisory reports, remuneration plans, and other corporate governance matters. The document includes detailed voting results and legal witness statements confirming the validity of the meeting and voting process. It does not contain the full annual report or financial statements themselves but reports on the resolutions passed at the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)' rather than the full Annual Report (10-K) or AGM Information presentation (AGM-R). The document length is about 4721 characters, which is consistent with a detailed voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2025-05-13 Chinese
中信证券股份有限公司关于深圳惠泰医疗器械股份有限公司持续督导保荐总结报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导保荐总结报告书" (Continuous Supervision Sponsorship Summary Report) issued by a sponsor (中信证券股份有限公司) regarding 深圳惠泰医疗器械股份有限公司. It discusses the continuous supervision period from January 7, 2021 to December 31, 2024, related to the company's IPO and ongoing compliance with regulatory requirements. The document includes details about the IPO, fundraising, regulatory compliance, information disclosure, and sponsor's supervisory activities. It is not a full annual or interim financial report, nor an earnings release or audit report. It is a summary report related to the sponsor's continuous supervision duties post-IPO, which is a specialized regulatory report related to capital markets and sponsorship activities. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory compliance and supervision summary rather than a financial report or announcement of voting results, management changes, or capital changes. The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2025-05-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.